Arizona Sends $10 Million to Sheriff's Offices for Reentry. The Test Is What Happens After the Cell Door Opens.

The first two weeks after release from jail or prison are the most dangerous of a person’s life if they have a substance use disorder. Their tolerance has fallen to near zero from weeks of forced abstinence. Their stress has spiked from the immediate chaos of reentry — finding housing, reporting to a probation officer, navigating benefits that lapsed while incarcerated. And if they have an opioid use disorder, they are heading back into a community where the drug supply contains carfentanil. The gap between those two facts is where people die.

Arizona Attorney General Kris Mayes recently announced the allocation of $10 million in opioid settlement funds to five county sheriff’s offices — $2 million each — to strengthen reentry programs for people transitioning out of incarceration. The announcement is part of Arizona’s broader deployment of its $1.215 billion in multi-decade settlement funds from opioid litigation.

The money is real. The test is whether it reaches the two weeks that matter most.

Maricopa County has already been moving in the right direction. The county is using settlement funds to expand medications for opioid use disorder (MOUD) — buprenorphine and methadone — in jails: starting medication-assisted treatment during incarceration and connecting people to community providers before release, so there is no treatment gap at the moment the cell door opens. This is evidence-based. Studies consistently show that people who begin MOUD while incarcerated and are linked to community care have dramatically lower rates of fatal overdose in the reentry window.

What makes the sheriff’s office designation interesting — and worth watching — is that sheriffs run county jails, where the majority of short-term incarceration happens in Arizona. State prisons hold people serving longer sentences; county jails hold people serving days, weeks, or months, often pretrial. The jail population has historically been harder to reach with sustained treatment because stays are shorter and discharge happens faster. If these funds go toward MAT initiation and community linkage at jail level — not just job training and housing navigation, which are important but don’t address the overdose risk — they could have an outsized effect on the reentry mortality window.

If you are working in a jail-adjacent organization in one of these five counties: the settlement funds are coming, and the planning conversations about how to deploy them are happening now. The window to push for treatment-first programming — specifically medication initiation plus same-day linkage to a community prescriber — is before the money is already committed to non-clinical reentry services that don’t reduce overdose mortality.

The cell door still opens into a drug supply that doesn’t forgive the tolerance that incarceration created. Two weeks. That is the window. Whether $10 million reaches it is the question.